FDA's Drug Safety Changes: Safe Legislation; Unsafe Climate
This article was originally published in RPM Report
Executive Summary
The Kennedy-Enzi bill is off to a fast start as the presumptive vehicle for drug safety reforms in 2007. It could stabilize the drug approval process and improve a deteriorating climate for FDA decisions.
You may also be interested in...
The Billion Dollar REMS: Xenazine and the Value of Facing Regulatory Realities
Prestwick's Huntington's chorea therapy won FDA approval in August, triggering a flurry of deals valued at over $1 billion. Not bad for a 50-year-old drug expected to treat no more than 5,000 patients-and a powerful case study in how embracing the new regulatory realities can pay off.
The Billion Dollar REMS: Xenazine and the Value of Facing Regulatory Realities
Prestwick's Huntington's chorea therapy won FDA approval in August, triggering a flurry of deals valued at over $1 billion. Not bad for a 50-year-old drug expected to treat no more than 5,000 patients-and a powerful case study in how embracing the new regulatory realities can pay off.
The REMS Era Begins: FDA Applies Soft Touch With New Drug Safety Tools
Congress gave FDA some tough new tools to regulate drugs in September, but no one could know for sure how FDA would use them. Now there is some actual real world experience to judge by: a half-dozen drugs approved by FDA are subject to either a Risk Evaluation & Mitiagation Strategy or a mandatory post-marketing commitment. So far, the news is good for drug developers.